AdamasLogo_noTM.jpg
Adamas Provides Preliminary Fourth Quarter and Full Year 2020 Total Revenues and Key Business Drivers for 2021
13 janv. 2021 09h15 HE | Adamas Pharmaceuticals, Inc.
-- Total revenues expected to be $20.8 million for fourth quarter 2020 and $74.2 million for full year 2020 -- -- Product sales of GOCOVRI® expected to be $19.8 million for fourth quarter 2020 and...
AdamasLogo_noTM.jpg
Adamas to Present at Upcoming ICR Conference
07 janv. 2021 18h02 HE | Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to...
AdamasLogo_noTM.jpg
Adamas Completes Acquisition of OSMOLEX ER®
05 janv. 2021 09h15 HE | Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to...
AdamasLogo_noTM.jpg
Adamas to Present at Upcoming H.C. Wainwright Conference
04 janv. 2021 16h15 HE | Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to...
AdamasLogo_noTM.jpg
Adamas Announces New Employment Inducement Grant
11 déc. 2020 16h02 HE | Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new...
AdamasLogo_noTM.jpg
Adamas Announces Agreement to Amend Royalty-Backed Loan Agreement with HealthCare Royalty Partners
02 déc. 2020 06h51 HE | Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to...
AdamasLogo_noTM.jpg
Adamas Announces Agreement to Settle Patent Litigation with Osmotica
02 déc. 2020 06h50 HE | Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to...
AdamasLogo_noTM.jpg
Adamas to Present at Upcoming Evercore ISI Conference
24 nov. 2020 16h03 HE | Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to...
AdamasLogo_noTM.jpg
Adamas announces changes to its Board of Directors with the appointment of Spyros Papapetropoulos and the retirement of Ivan Lieberburg
23 nov. 2020 09h15 HE | Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to...
AdamasLogo_noTM.jpg
Adamas to Present at Upcoming Piper Sandler Conference
18 nov. 2020 16h02 HE | Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to...